Financials Oncimmune Holdings plc

Equities

ONC

GB00BYQ94H38

Pharmaceuticals

Market Closed - London S.E. 11:35:27 2024-05-21 am EDT 5-day change 1st Jan Change
25.6 GBX +2.81% Intraday chart for Oncimmune Holdings plc +5.35% +1.59%

Valuation

Fiscal Period: August 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 69.59 59.1 93.03 129.2 61.73 17.19 18.97 -
Enterprise Value (EV) 1 56.64 59.1 95.7 129 61.73 17.19 23.37 21.57
P/E ratio -9.9 x - -11 x -26.1 x -5.39 x 4.1 x -7.11 x 34.6 x
Yield - - - - - - - -
Capitalization / Revenue 290 x 346 x 183 x 34.7 x 16.3 x - 6.72 x 2.74 x
EV / Revenue 236 x 346 x 188 x 34.7 x 16.3 x - 8.28 x 3.12 x
EV / EBITDA -9.14 x - -10.9 x -29.3 x - - -10.6 x 14.3 x
EV / FCF - - -10.5 x -25.9 x - - -6.49 x 12.7 x
FCF Yield - - -9.55% -3.85% - - -15.4% 7.88%
Price to Book 4.63 x - -473 x 24.7 x - - - -
Nbr of stocks (in thousands) 61,588 63,212 63,503 69,084 69,437 74,104 74,104 -
Reference price 2 1.130 0.9350 1.465 1.870 0.8890 0.2320 0.2560 0.2560
Announcement Date 10/31/18 10/31/19 10/30/20 11/2/21 2/27/23 2/29/24 - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: August 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 0.24 0.171 0.509 3.722 3.788 - 2.822 6.915
EBITDA 1 -6.194 - -8.768 -4.405 - - -2.195 1.508
EBIT 1 -6.374 - -9.268 -5.145 - - -2.027 1.046
Operating Margin -2,655.83% - -1,820.83% -138.23% - - -71.83% 15.13%
Earnings before Tax (EBT) 1 -6.342 - -9.783 -5.696 - - -2.676 0.552
Net income 1 -6.342 - -8.459 -4.628 - 4.104 -2.669 0.552
Net margin -2,642.5% - -1,661.89% -124.34% - - -94.58% 7.98%
EPS 2 -0.1141 - -0.1336 -0.0717 -0.1649 0.0566 -0.0360 0.007400
Free Cash Flow 1 - - -9.139 -4.973 - - -3.6 1.7
FCF margin - - -1,795.48% -133.61% - - -127.57% 24.58%
FCF Conversion (EBITDA) - - - - - - - 112.73%
FCF Conversion (Net income) - - - - - - - 307.97%
Dividend per Share - - - - - - - -
Announcement Date 10/31/18 10/31/19 10/30/20 11/2/21 2/27/23 2/29/24 - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: August 2024 S2
Net sales 1 1.636
EBITDA 1 -0.838
EBIT 1 -1.269
Operating Margin -77.57%
Earnings before Tax (EBT) 1 -1.57
Net income 1 -1.57
Net margin -95.97%
EPS 2 -0.0212
Dividend per Share -
Announcement Date -
1GBP in Million2GBP
Estimates

Balance Sheet Analysis

Fiscal Period: August 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - 2.67 - - - 4.4 2.6
Net Cash position 1 13 - - 0.14 - - - -
Leverage (Debt/EBITDA) - - -0.3044 x - - - -2.005 x 1.724 x
Free Cash Flow 1 - - -9.14 -4.97 - - -3.6 1.7
ROE (net income / shareholders' equity) -68.3% - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 0.2400 - -0 0.0800 - - - -
Cash Flow per Share -0.1100 - - - - - - -
Capex 1 0.03 - 0.24 0.45 - - 0.07 0.08
Capex / Sales 12.92% - 46.37% 11.98% - - 2.48% 1.08%
Announcement Date 10/31/18 10/31/19 10/30/20 11/2/21 2/27/23 2/29/24 - -
1GBP in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. ONC Stock
  4. Financials Oncimmune Holdings plc
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW